Artificial intelligence (AI) has emerged as a promising clinical tool in oncology, though its maturity and applicability differ substantially between diseases. This review explores the differences and similarities in AI applications for breast cancer and brain cancer diagnosis and treatment.

This article provides an overview for primary cardiac sarcoma in regards to diagnostics, treatments and the use of artificial intelligence (AI) as a possible tool. It argues that AI can be utilised to aid with individualised treatment, ultimately improving prognosis and patient outcomes.

This review examines how alcohol and opioids modify the epigenome in key brain regions, contributing to anxiety, depression, post-traumatic stress disorder and addiction vulnerability. It also summarises evidence from animal and human studies demonstrating that these epigenetic alterations can be transmitted across generations.

This paper explores how errors in the age-related epigenomes cause gene mutations, stem-cell exhaustion and malignant transformations, contributing to the development of cancer. It investigates emerging technologies, such as CRISPR-based epigenome editing, and their potential to reduce cancer risk before it begins.

Artificial intelligence is rapidly emerging as a transformative tool in breast cancer care, with applications ranging from mammogram interpretation to risk stratification and clinical decision support. While these technologies hold considerable promise, their integration into healthcare raises ethical issues. This paper examines four critical regions of this implementation: ethical guidelines, data privacy, responsibility and accessibility.